Concepedia

Jian-Ri Li

JL

Statistics

Publications

3

Citations

886

H-Index

3

Active since

2015

Affiliations

Taichung Veterans General Hospital(Current)

Universitat de Barcelona

National and Kapodistrian University of Athens

Institut d'Investigació Biomédica de Bellvitge

Institut Català d'Oncologia

Jian-Ri Li is an author at Taichung Veterans General Hospital specializing in urothelial carcinoma, medicine, and metastatic urothelial carcinoma immunotherapy.

Publications per year

2015–2020

3

Publications

3

Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial

Matthew D. Galsky, Jóse Ángel Arranz Arija, Aristotelis Bamias et al. · The Lancet · 2020 · 787 citations · Full text

, , +13

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

Daniel P. Petrylak, Ronald de Wit, Kim N. et al. · The Lancet Oncology · 2019 · 85 citations · Full text

, , +16

Gab1 is essential for membrane translocation, activity and integrity of mTORCs after EGF stimulation in urothelial cell carcinoma

Chi-Hao Chang, Po-Chao Chan, Jian-Ri Li et al. · Oncotarget · 2015 · 14 citations · Full text

, , +8

1–3 of 3